---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-008621"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:07:17.563653+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AcelRx restates interim 2022 financials due to EPS error; divests DSUVIA to Alora for royalties and milestones

## Summary
- Non-reliance on Q2 and Q3 2022 financials due to EPS calculation error (two-class method for warrants); no impact on cash, revenue, or net income.
- Divests DSUVIA to Alora Pharmaceuticals; receives 15% royalty on commercial sales, 75% on DoD sales, and up to $116.5M in milestones.
- Cash and short-term investments $20.8M as of Dec 31, 2022; Q4 2022 net loss $7.5M ($1.00 per share) vs $7.9M ($1.24) in Q4 2021.
- Full-year 2022 DSUVIA net sales $1.8M, up 76% YoY; combined R&D and SG&A expenses $7.3M in Q4 2022.
- Niyad (nafamostat) EUA submission planned for Q2 2023; Fedsyra NDA submission by end of Q2 2023.

## SEC filing metadata
- accession: 0001437749-23-008621
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774923008621/0001437749-23-008621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774923008621/acrx20230330_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-008621
- JSON: https://secwatch.observer/filing/0001437749-23-008621.json
- Plain text: https://secwatch.observer/filing/0001437749-23-008621.txt

## Key facts
- Auditor Changes
  TALPHERA, INC. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: On March 30, 2023, the Company's management and the Audit Committee of the Company determined that the Company's Prior Period Financial Statements for the Interim Periods, should no longer be relied upon because of the error in the earnings per share calculations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427925/000143774923008621/0001437749-23-008621-index.htm
- Earnings Releases
  TALPHERA, INC. reported financial results for full year and fourth quarter 2022.
  - Period: full year and fourth quarter 2022
  - Result: reported results
  source text: AcelRx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2022 and providing a corporate update (the “Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427925/000143774923008621/0001437749-23-008621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.